A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2022-05-06
Adverse events
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-08 (study day 294); relationship: not assessed
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-06-30 (study day 408); relationship: N
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-08-16 (study day 455); relationship: not assessed
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-09-29 (study day 499); relationship: N
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-12-30 (study day 591); relationship: N
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2024-02-07 (study day 630); relationship: not assessed
Data queries
No data queries.